Tim Eisen

7PUBLICATIONS
76CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 16, 2026
Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor-Resistant Patients in Clear Cell Renal Cell Carcinoma.

|Sep 09, 2024
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.

Fiona Collinson, Kara-Louise Royle, Jayne Swain

|Jun 24, 2022
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.

Meta H M Diekstra, Jesse J Swen, Loes F M van der Zanden

|Feb 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.

Bhavna Oza, Tim Eisen, Eleni Frangou

|Jan 21, 2022
Hyperpolarized 13C-Pyruvate Metabolism as a Surrogate for Tumor Grade and Poor Outcome in Renal Cell Carcinoma-A Proof of Principle Study.

Stephan Ursprung, Ramona Woitek, Mary A McLean

|Feb 17, 2021
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.

Andrew J Armstrong, Andrew B Nixon, Andrea Carmack

Pageof 2

Frequent Collaborators

4 joint publications

Grant D Stewart

3 joint publications

Angela Meade

2 joint publications

Axel Bex

2 joint publications

Eleni Frangou